Vernal Keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. It is an IgE‐ and T cell‐mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal, and the mixed form. Large papillae of different shape and size, usually greater than 1 mm in diameter, on the upper tarsal conjunctiva characterizes the tarsal form, while trantas’ dots and infiltrates on the limbus are typical traits of the limbal form. The mixed form is characterized by the presence of both forms in the same eye. It is most often seen in boys and tends to resolve at puberty.
DelveInsight's "Vernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Vernal keratoconjunctivitis market report also covers emerging drugs, current treatment practices, Vernal keratoconjunctivitis market share of the individual therapies, current and forecasted Vernal keratoconjunctivitis Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Vernal keratoconjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Vernal keratoconjunctivitis Market Key Facts
-
Vernal Keratoconjunctivitis may represent as 3% of serious ophthalmic disease. In addition, the prevalence is about 1 in 5000 cases of eye disease in Northern Europe and North America.
-
According to the World Allergy Organization, males are more frequently affected than females, with a ratio of 3:1. The disease usually begins before the age of 10 years and remits at the time of puberty, although the age of affected individuals ranges from 3 to 25 years of age.
Key Benefits of Vernal keratoconjunctivitis Market Report
-
Vernal keratoconjunctivitis market report provides an in-depth analysis of Vernal keratoconjunctivitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Vernal keratoconjunctivitis market report will help in developing business strategies by understanding the Vernal keratoconjunctivitis Market trends & developments, key players and future market competition that will shape and drive the Vernal keratoconjunctivitis market in the upcoming years.
-
The Vernal keratoconjunctivitis market report covers Vernal keratoconjunctivitis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Vernal keratoconjunctivitis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Vernal keratoconjunctivitis Market
The Vernal keratoconjunctivitis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Vernal keratoconjunctivitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Vernal keratoconjunctivitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Vernal keratoconjunctivitis Epidemiology
The Vernal keratoconjunctivitis epidemiology section covers insights about historical and current Vernal keratoconjunctivitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Vernal keratoconjunctivitis Drugs Uptake and Key Market Players
The Vernal keratoconjunctivitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal keratoconjunctivitis market or expected to get launched in the market during the study period. The analysis covers Vernal keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
For more information on Vernal keratoconjunctivitis Market, visit:
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market